Menumenu
  • Home
  • CNS diseases Publications

CNS diseases Publications

CNS diseases Publications

  • Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures.Abstract

    AIM: Both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) have been associated with an increased risk of fractures. The serotonin transporter (5-HTT) has been located in the bone and may play a role in bone physology. We assessed the association between antidepressant drug use, categorized in a therapeutical-based way and on basis of their affinity for the 5-HTT, and the risk of both osteoporotic and non-osteoporotic fractures

    Verde l BM, Souverein PC, Egberts TC, van Staa TP, Leufkens HG, de Vries F. Bone. 2010 Sep; 47 (3): 604-9.
  • Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.Abstract

    BACKGROUND: The cholinesterase inhibitors (ChEIs) rivastigmine and galantamine have been approved for the treatment of mild to moderate Alzheimer’s disease in the Netherlands. Differences between ChEIs regarding persistence or the use of effectiveoses in daily clinical practice have been observed. However, most studies assessing ChEI discontinuation and associated determinants have been conducted in North America and there is a lack of knowledge about ChEI discontinuation and its determinants indaily clinical practice in Europe

    Kroger E, van Marum R, Souverein P, Egberts T. Drugs Aging. 2010 Aug 1; 27 (8): 663-75.
  • Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder.Abstract

    OBJECTIVES: Administration to rats of mood stabilizers approved for bipolar disorder (BD) downregulates markers of the brain arachidonic acid (AA, 20:4n-6) metabolic cascade, including phospholipase A(2) (PLA(2)) and cyclooxygenase (COX) expressionWe hypothesized that other agents that target the brain AA cascade, nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids, also would ameliorate BD symptoms

    Stolk P, Souverein PC, Wilting I, Leufkens HG, Klein DF, Rapoport SI, Heerdink ER. Prostaglandins Leukot Essent Fatty Acids. 2010 Jan; 82 (1): 9-14.
  • Use of anti-depressants and the risk of fracture of the hip or femur.Abstract

    SUMMARY: Anti-depressants are used largely, but have serious side effects. We show that both selective serotonin re-uptake inhibitors (SSRIs) and tricyclic anti-depressants (TCAs) increase the risk of hip/femur fracture and that this risk is time rlated and depends on the degree of serotonin transporter inhibition

    van den Brand MW, Samson MM, Pouwels S, van Staa TP, Thio B, Cooper C, Leufkens HG, Egberts AC, Verhaar HJ, deVries F. Osteoporos Int. 2009 Oct; 20 (10): 1705-13.
  • Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study.Abstract

    This case-control study showed that current use of conventional antipsychotics, but not atypical antipsychotics, seems to be associated with an increased risk of a hip/femur fracture, possibly related to the pharmacological properties of conventionl antipsychotics. Furthermore, no evidence for a dose effect was found

    Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F. Osteoporos Int. 2009 Sep; 20 (9): 1499-506.
  • Does the length of the first antidepressant treatment episode influence risk and time to a second episode?.Abstract

    Antidepressant treatment in primary care is inconsistent with treatment recommendations, and many patients discontinue treatment within 6 months. How this affects treatment outcomes is unknown. The aim of this study was to assess how length of theirst antidepressant episode influences risk and time to a second treatment episode within 5 years

    Gardarsdottir H, van Geffen EC, Stolker JJ, Egberts TC, Heerdink ER. J Clin Psychopharmacol. 2009 Feb; 29 (1): 69-72.
  • Influence of antidepressants on glycaemic control in patients with diabetes mellitus.Abstract

    PURPOSE: Anecdotal evidence suggests that antidepressants (ADs) may complicate glycaemic control. The objective of this longitudinal study was to investigate the influence of ADs on glycaemic control within diabetes patients. METHODS: From the pharacy registry database PHARMO, we selected insulin users who did not use oral antidiabetics

    Knol MJ, Derijks HJ, Geerlings MI, Heerdink ER, Souverein PC, Gorter KJ, Grobbee DE, Egberts AC. Pharmacoepidemiol Drug Saf. 2008 Jun; 17 (6): 577-86.
  • Antipsychotic drug use and risk of pneumonia in elderly people.Abstract

    OBJECTIVES: To investigate the association between antipsychotic drug use and risk of pneumonia in elderly people. DESIGN: A nested case-control analysis. SETTING: Data were used from the PHARMO database, which collates information from community parmacies and hospital discharge records. PARTICIPANTS: A cohort of 22,944 elderly people with at least one antipsychotic prescription; 543 cases of hospital admission for pneumonia were identified

    Knol W, van Marum RJ, Jansen PA, Souverein PC, Schobben AF, Egberts AC. J Am Geriatr Soc. 2008 Apr; 56 (4): 661-6.
  • The association between antidepressant use and hypoglycaemia in diabetic patients: a nested case-control study.Abstract

    PURPOSE: Hypoglycaemia is a limiting factor for glycaemic management of diabetes with intensive insulin and/or oral antidiabetic drug (OAD) regimen. Case reports suggest that antidepressants may interfere with blood glucose metabolism in patients wth diabetes mellitus potentially increasing the risk of clinically relevant hypoglycaemia

    Derijks HJ, Heerdink ER, DeKoning FH, Janknegt R, Klungel OH, Egberts AC. Pharmacoepidemiol Drug Saf. 2008 Apr; 17 (4): 336-44.
  • No increased incidence of diabetes in antidepressant users.Abstract

    This study investigated whether the association between depression and diabetes was influenced by the presence of chronic somatic disease. To distinguish between depression and other psychosocial complaints, we studied the onset of diabetes in antiepressant (AD) users and benzodiazepine (BD) users, respectively

    Knol MJ, Geerlings MI, Egberts AC, Gorter KJ, Grobbee DE, Heerdink ER. Int Clin Psychopharmacol. 2007 Nov; 22 (6): 382-6.